Skip to main content

Advertisement

SpringerLink
Log in

Pharmacologic Resistance in Prolactinoma Patients

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Pharmacologic resistance to dopamine agonists is defined here as failure to normalize PRL levels and failure to decrease macroprolactinoma size by ≥50%. Failure to normalize PRL levels is found in about one-quarter of patients treated with bromocriptine and 10–15% of those treated with pergolide or cabergoline. Failure to achieve at least a 50% reduction in tumor size occurs in about one-third of those treated with bromocriptine and 10–15% of those treated with pergolide or cabergoline. The cause of dopamine resistance is primarily a decrease in D2 receptors but the receptors have normal affinity for dopamine.

Treatment approaches for patients resistant to dopamine agonists include changing to another dopamine agonist and increasing the dose of the drug as long as there is continued response to the dose increases and no adverse effects with higher doses. Transsphenoidal surgery is also an option. Clomiphene, gonadotropins, and GnRH can be used if fertility is desired. For those not desiring fertility, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. In many patients modest or even no reduction in tumor size may be acceptable as long as there is not tumor growth. Hormone replacement (estrogen or testosterone) may cause a decrease in efficacy of the dopamine agonist so that it must be carried out cautiously. Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin N Amer 2001;30:585–610.

    CAS  Google Scholar 

  2. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003;65:19–27.

    Google Scholar 

  3. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: insights into pathogenesis and therapy. Curr Opin Obstet Gynecol 1994;6:393–397.

    CAS  PubMed  Google Scholar 

  4. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989;342:926–929.

    Article  CAS  PubMed  Google Scholar 

  5. DeCamilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979;278:252–254.

    CAS  Google Scholar 

  6. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Giα proteins to inhibit adenylyl cyclase. J Biol Chem 1994;269:23120–23127.

    CAS  PubMed  Google Scholar 

  7. Rasolonjanahary R, Gerard C, Dufour MN, Homburger V, Enjalbert A, Guillon G. Evidence for a direct negative coupling between dopamine-D2 receptors and PLC by heterotrimeric Gi1/2 proteins in rat anterior pituitary cell membranes. Endocrinology 2002;143:747–754.

    Article  CAS  PubMed  Google Scholar 

  8. Vallar L, Vicentini LM, Meldolesi J. Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem 1988;263:10127–10134.

    CAS  PubMed  Google Scholar 

  9. Liu JC, Baker RE, Sun C, Sundmark VC, Elsholtz HP. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem 2002;277:35819–35825.

    CAS  PubMed  Google Scholar 

  10. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E. Control of lactotroph proliferation by dopamine: essential role of signaling through D2 receptors and ERKS. PNAS 2002;99:14530–14535.

    Article  CAS  PubMed  Google Scholar 

  11. Tindall GT, Kovacs Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:1178–1183.

    CAS  PubMed  Google Scholar 

  12. Bassetti M, Spada A, Pezzo G, Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 1984;58:268–273.

    CAS  PubMed  Google Scholar 

  13. Stefaneanu L, Kovacs K, Scheithauer BW, Konogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocrine Pathol 2000;11:341–352.

    CAS  Google Scholar 

  14. Aoki MDP, Aoki A, Maldonado CA. Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine. Histochem Cell Biol 2001;116:215–222.

    CAS  PubMed  Google Scholar 

  15. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500–509.

    CAS  PubMed  Google Scholar 

  16. Brue T, Pellegrini I, Gunz G, Morange I, DeWailly D, Brownell J, Enjalbert A, Jaquet P. Effects of the dopamine agonist CV 205–502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577–584.

    Article  CAS  PubMed  Google Scholar 

  17. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinomas intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454–456.

    CAS  PubMed  Google Scholar 

  18. DiSarno A, Landi ML, Cappabianca P, DiSalle F, Rossi FW, Pivonello R, DiSomma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256–5261.

    CAS  Google Scholar 

  19. Cannavó S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 1999;22:306–309.

    PubMed  Google Scholar 

  20. Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini PG, Liuzzi A. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest 1983;6:47–50.

    CAS  PubMed  Google Scholar 

  21. Delgrange E, Crabbé J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 1998;49:250–253.

    Article  CAS  PubMed  Google Scholar 

  22. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;2962–2965.

  23. Maurer RA. Estradiol regulates the transcription of the prolactin gene. J Biol Chem 1982;257:2133–2136.

    CAS  PubMed  Google Scholar 

  24. Shull JD, Gorski J. Estrogen regulates the transcription of the rat prolactin gene in vivo through at least two independent mechanisms. Endocrinology 1985;116:2456–2462.

    CAS  PubMed  Google Scholar 

  25. Lloyd GM, Meares JD, Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 1975;255:497–498.

    Article  CAS  PubMed  Google Scholar 

  26. Raymond V, Beaulieu M, Labrie F, Boissier J. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 1979;200:1173–1175.

    Google Scholar 

  27. West B, Dannies PS. Effects of estradiol on prolactin production and dihydroergocryptine-induced inhibition of prolactin production in primary cultures of rat pituitary cells. Endocrinology 1980;106:1108–1113.

    CAS  PubMed  Google Scholar 

  28. Jaquet P, Gunz G, Grisoli F. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Horm Res 1985;22:153–163.

    CAS  PubMed  Google Scholar 

  29. Heiman ML, Ben-Jonathan N. Rat anterior pituitary dopaminergic receptors are regulated by estradiol during lactation. Endocrinology 1982;111:1057–1060.

    CAS  PubMed  Google Scholar 

  30. Pasqualini C, Bojda F, Kerdelhué B. Direct effect of estradiol on the number of dopamine receptors in the anterior pituitary of ovariectomized rats. Endocrinology 1986;119:2484–2489.

    CAS  PubMed  Google Scholar 

  31. Nansel DD, Gudelsky GA, Reymond MJ, Porter JC. Estrogen alters the responsiveness of the anterior pituitary gland to the actions of dopamine on lysosomal enzyme activity and prolactin release. Endocrinology 1981;108:903–907.

    CAS  PubMed  Google Scholar 

  32. Páez-Pereda M, Giacomini D, Refojo D, Hagashima AC, Hopfner U, Grübler Y et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003;100:1034–1039.

    PubMed  Google Scholar 

  33. Lamberts SWJ, Verleun T, Hofland L, Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 1986;63:1342–1347.

    CAS  PubMed  Google Scholar 

  34. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44(Suppl):1121–1126.

    CAS  PubMed  Google Scholar 

  35. Reyniak JV, Wenof M, Aubert JM, Stangel JJ. Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 1980;55:8–11.

    CAS  PubMed  Google Scholar 

  36. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 1985;65:506.

    CAS  PubMed  Google Scholar 

  37. Abu-Fadil S, DeVane G, Siler TM, Yen SS. Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception 1976;13:79–95.

    Article  CAS  PubMed  Google Scholar 

  38. Davis JRE, Selby C, Jeffcoate WJ. Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol 1984;20:427–434.

    CAS  Google Scholar 

  39. Hwang PLH, Ng CSA, Cheong ST. Effect of oral contraceptives on serum prolactin: A longitudinal study in 126 normal premenopausal women. Clin Endocrinol 1986;24:127–133.

    CAS  Google Scholar 

  40. Josimovich JB, Lavenhar MA, Devanesan MM, Sesta H-J, Wilchins SA, Smith AC. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 1987;47:785–791.

    CAS  PubMed  Google Scholar 

  41. DeLeo V, Lanzetta D, Vanni AL, D’Antona D, Severi FM. Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 1991;44:155–161.

    CAS  Google Scholar 

  42. Grasso A, Baraghini F, Barbieri C, et al. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas 1982;4:19–26.

    Article  CAS  PubMed  Google Scholar 

  43. Perrone G, Falaschi P, Capri O, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 1994;39:202–207.

    CAS  PubMed  Google Scholar 

  44. Castel-Branco C, Martínez de Osaba MJ, Fortuny A, Iglesias X, González-Merlo J. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995;40:556–560.

    Google Scholar 

  45. Foth D, Römer T. Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 1997;44:124–126.

    Article  CAS  PubMed  Google Scholar 

  46. Schlegel W, Petersdorf LI, Juner R, Schulte H, Ebert C, von Eckardstein A. The effects of six months of treatment with a low-dose of conjugated estrogens in menopausal women. Clin Endocrinol 1999;51:643–651.

    Article  CAS  Google Scholar 

  47. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993;59:671–673.

    CAS  PubMed  Google Scholar 

  48. Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998;58:69–73.

    Article  CAS  PubMed  Google Scholar 

  49. Fahy UM, Foster PA, Torode HW, Hartog M, Hull MGR. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 1992;6:183–188.

    CAS  PubMed  Google Scholar 

  50. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. Arch Pathol Lab Med 1994;118:562.

    CAS  PubMed  Google Scholar 

  51. Garcia MM, Kapcala LP. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 1995;18:450–455.

    CAS  PubMed  Google Scholar 

  52. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 1987;64:391–394.

    CAS  PubMed  Google Scholar 

  53. Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002;87:4447–4451.

    Article  CAS  PubMed  Google Scholar 

  54. Fossati P, Strauch G, Tournaiaire J. Etude de l’activité de la bromocriptine dans les états d’hyperprolactinémie. Nouv Presse Med 1976;5:1687–1691.

    CAS  PubMed  Google Scholar 

  55. Friesen HG, Tolis G. The use of bromocriptine in the galactorrhoea-amenorrhoea syndromes: The Canadian Cooperative Study. Clin Endocrinol 1977;6(Suppl):91s–99s.

    Google Scholar 

  56. Bergh T, Nillius SJ, Wide L. Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol 1978;88:435–451.

    CAS  PubMed  Google Scholar 

  57. Badano AR, Miechi HR, Mirkin A, Arcángeli OA, Aparicio NJ, Rodríguez A, Oliva A, Turner D, Casas PRF. Bromocriptine in the treatment of hyperprolactinemic amenorrhea. Fertil Steril 1979;31:124–128.

    CAS  PubMed  Google Scholar 

  58. Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P, Dellabonanza D, Scarduelli C, Spelta B. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride. Fertil Steril 1982;37:61–67.

    CAS  PubMed  Google Scholar 

  59. Horowitz BL, Hamilton DJ, Sommers CJ, Bryan RN, Boyd AE III. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin. AJNR 1983;4:415–417.

    CAS  PubMed  Google Scholar 

  60. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.

    CAS  PubMed  Google Scholar 

  61. Liuzzi A, Dallabonzana D, Giuseppe MD, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656–659.

    Article  CAS  PubMed  Google Scholar 

  62. Van der Heijden PFM, de Wit W, Brownell J, Schoemaker J, Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 1991;40:111–118.

    Article  CAS  PubMed  Google Scholar 

  63. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 1992;38:84–89.

    CAS  PubMed  Google Scholar 

  64. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904–909.

    Article  CAS  PubMed  Google Scholar 

  65. Pascal-Vigneron V, Weryha G, Bose M, Leclere J. Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 1995;24:754–757.

    Google Scholar 

  66. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053–3057.

    Article  CAS  PubMed  Google Scholar 

  67. Sabancu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 2001;40:857–861.

    Google Scholar 

  68. Essais O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, et al. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol 2002;63:524–531.

    CAS  Google Scholar 

  69. Kleinberg DL, Boyd AE III, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T, Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704–709.

    Article  CAS  PubMed  Google Scholar 

  70. L’Hermite M, Debusschere PM, Gillet C, Deschepper C. Treatment of hyperprolactinaemic patients with pergolide. Acta Endocrinol 1983;103:441–445.

    CAS  PubMed  Google Scholar 

  71. Freda PU, Andreadis CI, Knandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8–13.

    Article  CAS  PubMed  Google Scholar 

  72. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280–1286.

    PubMed  Google Scholar 

  73. Lanier WL. Additional insights into pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:684–686.

    PubMed  Google Scholar 

  74. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US. Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730–731.

    Article  PubMed  Google Scholar 

  75. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179–1183.

    CAS  PubMed  Google Scholar 

  76. Ferrari C, Mattei A, Melis GB, et al. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201–1206.

    CAS  PubMed  Google Scholar 

  77. Ferrari C, Paracchi A, Mattei AM, de Vincentils S, D'Alberton A, Crosignani PG. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489–494.

    CAS  PubMed  Google Scholar 

  78. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537–546.

    CAS  PubMed  Google Scholar 

  79. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.

    CAS  PubMed  Google Scholar 

  80. Colao A, DiSarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, DiSalle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2246–2252.

    Google Scholar 

  81. Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980;50:1026–1033.

    Article  CAS  PubMed  Google Scholar 

  82. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinol 1994;60:314–322.

    CAS  Google Scholar 

  83. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A. Alteration of Gα subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 1996;8:737–746.

    Article  CAS  PubMed  Google Scholar 

  84. Ahmed SR, Shalet SM. Discordant responses of prolactinomas to two different dopamine agonists. Clin Endocrinol 1986;24:421–426.

    CAS  Google Scholar 

  85. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991;27:375–379.

    CAS  PubMed  Google Scholar 

  86. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM. Effect of the new dopaminergic agonist CV205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol 1991;34:25–29.

    CAS  Google Scholar 

  87. Razzaq R, O’Halloran DJ, Beardwell CG, Shalet SM. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. Horm Res 1993;39:218–222.

    Article  CAS  PubMed  Google Scholar 

  88. Merola B, Sarnacchiaro F, Colao A, DiSomma C, DiSarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C, Lombardi G. Positive response to compound CV205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994;8:175–181.

    CAS  PubMed  Google Scholar 

  89. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413–420.

    CAS  PubMed  Google Scholar 

  90. Rohmer V, Freneau E, Morange I, Simonetta C, and Le Club de l’Hypophyse. Efficiency of quinagolide in resistance to ergot-derived dopamine agonists: results of a multicenter study. Ann Endocrinol 2000;61:411–417.

    CAS  Google Scholar 

  91. Colao A, DiSarno A, Sarnacchiaro F, Ferone D, DiRenzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876–883.

    CAS  PubMed  Google Scholar 

  92. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202–212.

    Article  CAS  PubMed  Google Scholar 

  93. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, Schechtman E, Korczyn AD. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785–788.

    CAS  PubMed  Google Scholar 

  94. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Masso JFM, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R, and the PKDS009 Collaborative Study Group. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363–368.

    CAS  PubMed  Google Scholar 

  95. Radwanska E, McGarrigle HH, Little V, Lawrence D, Saris S, Swyer GI. Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin or bromocriptine. Fertil Steril 1979;32:187–192.

    CAS  PubMed  Google Scholar 

  96. Crosignani PG, Ferrari C, Scarduelli C, Picciotti MC, Caldara R, Malinverni A. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol 1981;58:708–713.

    CAS  PubMed  Google Scholar 

  97. Leyendecker G, Sruve T, Plotz EJ. Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol 1980;229:177–190.

    Article  CAS  PubMed  Google Scholar 

  98. De Quijada M, Timmermans HAT, Lamberts SWJ. Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. J Endocrinol 1980;86:109–116.

    CAS  PubMed  Google Scholar 

  99. Nagy I, Valdenegro CA, MacLeod RM. Effect of antiestrogens on pituitary prolactin production in normal and pituitary tumor-bearing rats. Neuroendocrinology 1980;30:389–395.

    CAS  PubMed  Google Scholar 

  100. Stalldecker G, Reynoso R, Piroli G, Cáceres N, DeNicola AF. Effects of dopamine and tamoxifen on serum prolactin and nuclear estrogen receptors in rat anterior pituitaries. Neuroendocrinol Lett 1993;15:389–395.

    CAS  Google Scholar 

  101. Lamberts SWJ, Verleun T, Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 1982;34:339–342.

    CAS  PubMed  Google Scholar 

  102. Volker W, Gehring WG, Berning R, Schmidt RC, Schneider J, von zur Mühlen A. Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 1982;101:491–500.

    CAS  PubMed  Google Scholar 

  103. Koizumi K, Aono T. Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas. Fertil Steril 1986;46:312–314.

    CAS  PubMed  Google Scholar 

  104. Yamashita M, Hirakawa T, Tashiro Y, Matsuda T, Kibe M, Fukushima T, et al. Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine. No Shinkei Geka 1987;15:65–72.

    CAS  PubMed  Google Scholar 

  105. Pinilla L, Gonzalez LC, Tena-Sempere M, Aguilar E. Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats. Neuroscience Lett 2001;311:149–152.

    Article  CAS  Google Scholar 

  106. Lasco A, Cannavó S, Gaudio A, Morabito N, Basile G, Nicita-Mauro V, Frisina N. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Eur J Endocrinol 2002;147:461–465.

    Article  CAS  PubMed  Google Scholar 

  107. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, dal Toso R, Balsari A, Spano PF. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993;90:7961–7965.

    CAS  PubMed  Google Scholar 

  108. Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Brit J Cancer 1995;72:1397–1399.

    CAS  PubMed  Google Scholar 

  109. Fiorentini C, Guerra N, Facchetti M, Finardi A, Tiberio L, Schiaffonati L, Spano P, Missale C. Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-κB. Mol Endocrinol 2002;16:353–366.

    Article  CAS  PubMed  Google Scholar 

  110. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Guiliani M, Stevens JC, Barbano R, Dyck PJ for the rhNGF Clinical Investigator Group. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. JAMA 2000;284:2215–2221.

    Article  CAS  PubMed  Google Scholar 

  111. Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC, and the AIDS Clinical Trials Group Team 291. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001;57:1313–1316.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue (Tarry 15-731), Chicago, 60611, IL

    Mark E. Molitch (Professor of Medicine)

Authors
  1. Mark E. Molitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Molitch.

Additional information

An updated version of a manuscript previously published in Pituitary [2].

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molitch, M.E. Pharmacologic Resistance in Prolactinoma Patients. Pituitary 8, 43–52 (2005). https://doi.org/10.1007/s11102-005-5085-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-005-5085-2

Key Words

Search

Navigation